journal article Open Access Dec 02, 2025

Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression

View at Publisher Save 10.1111/apt.70483
Abstract
ABSTRACT

Background
Despite achieving undetectable hepatitis B virus (HBV) DNA levels with nucleos(t)ide analogue (NA) therapy, patients with chronic hepatitis B (CHB) remain at risk of hepatocellular carcinoma (HCC). Novel covalently closed circular DNA activity biomarkers may improve risk stratification.


Aims
To comprehensively assess the association between serum HBV RNA and hepatitis B core‐related antigen (HBcrAg) levels, measured upon achieving undetectable HBV DNA levels, and subsequent HCC development in NA‐treated patients with CHB.


Methods
We retrospectively analysed 311 patients with CHB who achieved undetectable HBV DNA levels during NA therapy between 2000 and 2024. Serum HBV RNA (≥ 10 copies/mL) and HBcrAg (≥ 2.1 log U/mL) were measured in stored samples collected when HBV DNA first became undetectable. Cox regression analysis was performed to identify the factors associated with HCC development.


Results

During a median follow‐up of 11.0 years, 31 (10.0%) patients developed HCC. At viral suppression, 132 (42.4%) patients had HBV RNA ≥ 10 copies/mL. HCC incidence was significantly higher in patients with quantifiable HBV RNA than in those with unquantifiable HBV RNA (15‐year incidence, 17.8% vs. 8.8%,
p
 = 0.026). Quantifiable HBV RNA independently predicted HCC (adjusted hazard ratio [aHR], 3.313; 95% confidence interval [CI]: 1.154–9.507;
p
 = 0.026). HBcrAg showed no association (aHR, 0.821; 95% CI: 0.253–2.669;
p
 = 0.743). Patients with quantifiable HBV RNA and albumin‐bilirubin score ≥ −2.60 had the highest risk (5‐year incidence: 15.8%).



Conclusions
HBV RNA levels at viral suppression predict HCC development in NA‐treated patients with CHB, outperforming HBcrAg. Incorporating HBV RNA assessment can improve risk‐stratified HCC surveillance strategies.
Topics

No keywords indexed for this article. Browse by subject →

References
39
[1]
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

Tetsuya Hosaka, Fumitaka Suzuki, Masahiro Kobayashi et al.

Hepatology 10.1002/hep.26180
[22]
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade

Philip J. Johnson, Sarah Berhane, Chiaki Kagebayashi et al.

Journal of Clinical Oncology 10.1200/jco.2014.57.9151
[24]
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma

Bruno Sangro, Josepmaria Argemi, Maxime Ronot et al.

Journal of Hepatology 10.1016/j.jhep.2024.08.028
[25]
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

Amit G. Singal, Josep M. Llovet, Mark Yarchoan et al.

Hepatology 10.1097/hep.0000000000000466
[28]
[35]
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy

George Papatheodoridis, George Dalekos, Vana Sypsa et al.

Journal of Hepatology 10.1016/j.jhep.2015.11.035
Cited By
2
Alimentary Pharmacology & Thera...